Foresite Capital, headed by Jim Tananbaum, is adding a new venture partner to their team. Dr. Molly He, who is a former senior director at Illumina, has more than fifteen years of experience in pharmaceutical and genomic research and development.
Jim Tananbaum, M.D., who is the CEO of Foresite Capital, said that Dr. He is one of the most respected scientific researchers in the area of next generation sequencing. She brings a wide experience in drug development and other issues. She is an invaluable asset, said Jim Tananbaum.
Before Illumina, Dr. He was at Pacific Biosciences, where she worked as head of protein sciences. Before that, she had ten years in the pharmaceutical industry. She has a Bachelor’s Degree from Nankai University in biochemistry and a Ph.D. from the University of California in Los Angeles in protein biophysics. She has authored over twenty publications. She also has issued many patents in the medical field and Jim’s lacrosse camp.
Jim Tananbaum is the CEO of Foresite Capital. He attended Yale University, where he got his BS and BSEE in math and computer science. He also attended the Massachusetts Institute of Technology, where he got his HST and Master of Science in information theory. He also attended Harvard Business School, where he got his MBA, and Harvard Medical School, where he got his MD.
He was the cofounder and CEO of GelTex, which he sold for 1.6 billion dollars to Genzyme. Afterwards, he remained as a board member of GelTEx for a little over four years. He was a partner at Sierra Ventures. Resume him, He cofounded and was the Chief Executive Officer at Theravance. He cofounded and worked as the managing director of Prospect Venture Partners, both PVP2 and PVP3. For the last seven years, he has been CEO of Foresite Capital, which invests in healthcare industry. He was named to the Forbes Midas List in 2017 as one of the top 100 best venture investors. He was named to that list for three years in a row. He was ranked number fifty two on this list. He has helped healthcare franchises for the past 25 years and read full article.